← Back to guidelines
Ophthalmology73 papers

Ocular toxocariasis

Last edited: 4/14/2026

Overview

Ocular toxocariasis (OT) is an inflammatory condition of the eye caused by larval migration of Toxocara canis or Toxocara cati, leading to potentially severe ophthalmologic complications including vision loss 13.

Diagnosis

  • Serological Testing: Elevated IgG anti-Toxocara antibody titers are indicative of OT, with higher titers more frequently observed in probable cases compared to negative cases 1.
  • Clinical Presentation: Common symptoms include vision loss, often permanent, particularly in younger patients 3.
  • Funduscopic Findings: Inflammation predominantly affects the intermediate uvea, with right eye involvement more common in OT patients 1.
  • Demographic Factors: OT frequently affects children and young adults, with a higher prevalence in Southern regions of the United States 23.
  • Management

  • First-Line Treatment: Albendazole or diethylcarbamazine are commonly used anti-parasitic treatments, though specific dosing details are not provided in the abstracts 12.
  • Adjunctive Therapy: Corticosteroids may be employed to manage inflammation, though specific regimens are not detailed 2.
  • Monitoring: Regular ophthalmologic follow-up is essential to assess treatment efficacy and manage complications 2.
  • Special Populations

  • Pediatrics: OT predominantly affects children, with a median age of 8.5 years in reported cases 3.
  • Comorbidities: No specific management adjustments for comorbidities are detailed in the provided abstracts.
  • Key Recommendations

  • Serological Testing for Diagnosis: Utilize elevated IgG anti-Toxocara antibody titers for diagnosing OT (Evidence: Moderate 1).
  • Targeted Treatment with Anti-Parasitics: Initiate treatment with anti-parasitic agents such as albendazole or diethylcarbamazine (Evidence: Expert opinion 2).
  • Aggressive Management in Children: Given the higher prevalence in pediatric patients, prioritize early and aggressive management to prevent permanent vision loss (Evidence: Moderate 3).
  • References

    1 Rubinsky-Elefant G, Yamamoto JH, Hirata CE, Prestes-Carneiro LE. Toxocariasis: critical analysis of serology in patients attending a public referral center for ophthalmology in Brazil. Japanese journal of ophthalmology 2018. link 2 Woodhall D, Starr MC, Montgomery SP, Jones JL, Lum F, Read RW et al.. Ocular toxocariasis: epidemiologic, anatomic, and therapeutic variations based on a survey of ophthalmic subspecialists. Ophthalmology 2012. link 3 . Ocular toxocariasis--United States, 2009-2010. MMWR. Morbidity and mortality weekly report 2011. link 4 Jeanfaivre T, Cimon B, Tolstuchow N, de Gentile L, Chabasse D, Tuchais E. Pleural effusion and toxocariasis. Thorax 1996. link

    Original source

    1. [1]
      Toxocariasis: critical analysis of serology in patients attending a public referral center for ophthalmology in Brazil.Rubinsky-Elefant G, Yamamoto JH, Hirata CE, Prestes-Carneiro LE Japanese journal of ophthalmology (2018)
    2. [2]
      Ocular toxocariasis: epidemiologic, anatomic, and therapeutic variations based on a survey of ophthalmic subspecialists.Woodhall D, Starr MC, Montgomery SP, Jones JL, Lum F, Read RW et al. Ophthalmology (2012)
    3. [3]
      Ocular toxocariasis--United States, 2009-2010. MMWR. Morbidity and mortality weekly report (2011)
    4. [4]
      Pleural effusion and toxocariasis.Jeanfaivre T, Cimon B, Tolstuchow N, de Gentile L, Chabasse D, Tuchais E Thorax (1996)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG